Borregaard's operating revenues were NOK 1,605 million (NOK 1,770 million)2 in the 4th quarter of 2023. EBITDA1 was NOK 327 million (NOK 364 million). The result in BioSolutions improved while BioMaterials' and Fine Chemicals' results were lower compared with the 4th quarter of 2022. Operational issues at the Sarpsborg site and lower demand for and sales of biovanillin had a negative impact in the 4th quarter of approximately NOK 80 million.
In BioSolutions, reduced energy costs were partly offset by reduced sales volume and cost inflation in general. The reduced result in BioMaterials was mainly due to the operational issues at the Sarpsborg site. In Fine Chemicals, lower production volume and lower sales prices in fine chemical intermediates had a negative impact on EBITDA1 compared with the 4th quarter of 2022. The net currency effects were positive for the Group.
Profit before tax was NOK 135 million (NOK 210 million). Earnings per share were NOK 1.20 (NOK 1.85).
Full year 2023
Operating revenues increased to NOK 7,132 million (NOK 6,881 million). EBITDA1 reached an all-time high of NOK 1,781 million (NOK 1,643 million). Profit before tax was NOK 1,124 million (NOK 1,118 million). Earnings per share were NOK 8.73 (NOK 8.95).
- We are pleased to deliver an all-time high result in a year with challenging macroeconomic conditions, says President and CEO Per A. Sørlie.
Contacts:
Director Investor Relations, Knut-Harald Bakke, +47 905 79 164
Director Communications, Tone Horvei Bredal, +47 924 67 711
1. Operating profit before depreciation, amortisation and other income and expenses
2. Figures in parentheses are for the corresponding period in the preceding year
This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to Section 5 - 12 of the Norwegian Securities Trading Act.
This stock exchange announcement was published by Lotte Kvinlaug, Investor Relations Officer at Borregaard ASA, on 31 January 2024 at 07:00 CET.
